David Bodkin

3.8k total citations · 2 hit papers
26 papers, 3.1k citations indexed

About

David Bodkin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, David Bodkin has authored 26 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in David Bodkin's work include Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Diagnosis and Treatment (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). David Bodkin is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Diagnosis and Treatment (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). David Bodkin collaborates with scholars based in United States, Canada and Czechia. David Bodkin's co-authors include Ivor Royston, Ronald Levy, James A. Neidhart, Antonio J Grillo-López, B.K. Dallaire, Kenneth A. Foon, David G. Maloney, Thomas A. Davis, Russell J. Schilder and Nalini Janakiraman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Thoracic Oncology.

In The Last Decade

David Bodkin

26 papers receiving 3.0k citations

Hit Papers

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Thera... 1997 2026 2006 2016 1997 1997 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
    1997 1.4k citations David G. Maloney, Antonio J Grillo-López et al. Blood profile →
  2. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.
    1997 527 citations DG Maloney, A.J. Grillo-López et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Bodkin United States 17 1.3k 1.1k 759 752 719 26 3.1k
Catherine Spier United States 30 2.0k 1.5× 1.8k 1.6× 270 0.4× 857 1.1× 671 0.9× 73 3.6k
Philip Went Switzerland 30 2.4k 1.8× 1.4k 1.2× 354 0.5× 1.5k 2.0× 431 0.6× 86 4.7k
Klaus Beiske Norway 35 1.2k 0.9× 598 0.5× 352 0.5× 938 1.2× 589 0.8× 119 4.1k
Marcello Gambacorta Italy 31 1.8k 1.4× 1.0k 0.9× 216 0.3× 878 1.2× 515 0.7× 82 4.4k
Hans–Konrad Müller–Hermelink Germany 31 1.3k 1.0× 2.1k 1.9× 310 0.4× 580 0.8× 607 0.8× 64 3.9k
Ingrid Simonitsch‐Klupp Austria 29 586 0.4× 1.1k 1.0× 270 0.4× 356 0.5× 376 0.5× 93 2.4k
Loïc Ysebaert France 33 1.5k 1.1× 1.7k 1.5× 175 0.2× 804 1.1× 1.1k 1.6× 139 3.7k
Gunhild Mechtersheimer Germany 41 2.5k 1.8× 1.4k 1.2× 366 0.5× 1.8k 2.4× 595 0.8× 193 6.7k
Gunilla Enblad Sweden 38 2.3k 1.7× 3.0k 2.7× 267 0.4× 989 1.3× 1.4k 1.9× 200 5.3k
Bastian von Tresckow Germany 31 2.2k 1.6× 2.2k 2.0× 237 0.3× 383 0.5× 432 0.6× 159 3.6k

Countries citing papers authored by David Bodkin

Since Specialization
Citations

This map shows the geographic impact of David Bodkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Bodkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Bodkin more than expected).

Fields of papers citing papers by David Bodkin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Bodkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Bodkin. The network helps show where David Bodkin may publish in the future.

Co-authorship network of co-authors of David Bodkin

This figure shows the co-authorship network connecting the top 25 collaborators of David Bodkin. A scholar is included among the top collaborators of David Bodkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Bodkin. David Bodkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hinestrosa, Juan Pablo, Jean M. Lewis, Alfred Kinana, et al.. (2020). Simultaneous Isolation of Circulating Nucleic Acids and EV-Associated Protein Biomarkers From Unprocessed Plasma Using an AC Electrokinetics-Based Platform. Frontiers in Bioengineering and Biotechnology. 8. 581157–581157. 16 indexed citations
2.
Kelly, Karen, Christopher G. Azzoli, Petr Zatloukal, et al.. (2012). Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based Therapy. Journal of Thoracic Oncology. 7(6). 1041–1048. 26 indexed citations
3.
4.
Boasberg, Peter D., Charles H. Redfern, Gregory A. Daniels, et al.. (2011). Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. Cancer Chemotherapy and Pharmacology. 68(2). 547–552. 56 indexed citations
5.
Dean, John, et al.. (2010). Determining the Applicability and Effectiveness of Current CFD Methods in Store Certification Activities. 48th AIAA Aerospace Sciences Meeting Including the New Horizons Forum and Aerospace Exposition. 17 indexed citations
6.
Natale, Ronald B., David Bodkin, Ramaswamy Govindan, et al.. (2009). Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study. Journal of Clinical Oncology. 27(15). 2523–2529. 194 indexed citations
7.
Lynch, Thomas J., David Fenton, Vera Hirsh, et al.. (2009). A Randomized Phase 2 Study of Erlotinib Alone and in Combination with Bortezomib in Previously Treated Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 4(8). 1002–1009. 52 indexed citations
8.
Dean, John, et al.. (2008). Aircraft Stability and Control Characteristics Determined by System Identification of CFD Simulations. AIAA Atmospheric Flight Mechanics Conference and Exhibit. 36 indexed citations
9.
Butts, Charles, David Bodkin, Edward L. Middleman, et al.. (2007). Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 25(36). 5777–5784. 160 indexed citations
10.
Lynch, Thomas J., David Fenton, Vera Hirsh, et al.. (2007). Randomized phase II study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 25(18_suppl). 7680–7680. 5 indexed citations
11.
Butts, Charles, David Bodkin, Edward L. Middleman, et al.. (2007). Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 25(18_suppl). 7539–7539. 14 indexed citations
12.
Natale, Ronald B., David Bodkin, Ramaswamy Govindan, et al.. (2006). ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial. Journal of Clinical Oncology. 24(18_suppl). 7000–7000. 85 indexed citations
13.
Richards, Donald, Paul Richards, David Bodkin, Marcus A. Neubauer, & F. B. Oldham. (2005). Efficacy and Safety of Paclitaxel Poliglumex as First-Line Chemotherapy in Patients at High Risk with Advanced-Stage Non–Small-Cell Lung Cancer: Results of a Phase II Study. Clinical Lung Cancer. 7(3). 215–220. 23 indexed citations
14.
Bodkin, David, Ramaswamy Govindan, Bethany Sleckman, et al.. (2005). O-103 A comparison of the antitumour efficacy of ZD6474 and gefitinib(Iressa™) in patients with NSCLC: Results of a randomized, double-blind Phase II study. Lung Cancer. 49. S37–S37. 28 indexed citations
15.
16.
Gutheil, J., Tanya Campbell, Paul R. Pierce, et al.. (2000). Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3.. PubMed. 6(8). 3056–61. 308 indexed citations
17.
Maloney, David G., Antonio J Grillo-López, David Bodkin, et al.. (1997). IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma. Blood. 90(6). 2188–2195. 116 indexed citations
18.
Maloney, DG, A.J. Grillo-López, David Bodkin, et al.. (1997). IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.. Journal of Clinical Oncology. 15(10). 3266–3274. 527 indexed citations breakdown →
19.
Bodkin, David, et al.. (1995). Pharmacokinetic analysis of serum concentrations of the chimeric anti-CD20 antibody IDEC-C2B8 in patients with relapsed B cell lymphoma. 36. 365. 3 indexed citations
20.
Grillo-López, A.J., DG Maloney, David Bodkin, et al.. (1994). IDEC-C2B8. Journal of Immunotherapy. 16(3). 236–236. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Catherine Spier Breakdown of academic impact, for papers by Philip Went Breakdown of academic impact, for papers by Klaus Beiske Breakdown of academic impact, for papers by Marcello Gambacorta Breakdown of academic impact, for papers by Hans–Konrad Müller–Hermelink Breakdown of academic impact, for papers by Ingrid Simonitsch‐Klupp Breakdown of academic impact, for papers by Loïc Ysebaert Breakdown of academic impact, for papers by Gunhild Mechtersheimer Breakdown of academic impact, for papers by Gunilla Enblad Breakdown of academic impact, for papers by Bastian von Tresckow
Rankless by CCL
2026